Last updated: April 25, 2026
Who supplies the active pharmaceutical ingredient (API) for Selzentry (maraviroc)?
Maraviroc (Selzentry) is supplied as the active ingredient across global markets, with manufacturing and supply chains tied to the original developer (ViiV) and its network of API and dosage-form partners. The product’s commercial manufacturing footprint has historically included multiple contract manufacturing organizations (CMOs) and drug product sites rather than a single exclusive supplier.
Who manufactures the Selzentry drug product (tablets) across markets?
Selzentry is marketed as oral tablets containing maraviroc (commonly 150 mg and 300 mg strengths). Drug product supply is handled through a multi-site commercial network that changes by geography, regulatory requirements, and lot release strategy. The market-facing “supplier” view is typically represented by:
- Marketing authorization holder (MAH) and distribution entities (ViiV and local affiliates)
- Contract manufacturers for solid oral dosage manufacturing, packaging, and batch release
- API manufacturers feeding drug product sites
What supplier structure controls Selzentry supply in practice?
Selzentry supply is governed by two parallel layers of sourcing:
- API sourcing: raw material to API conversion at an approved site for maraviroc.
- Drug product conversion and release: API to tablets, plus coating, compression, packaging, and final batch certification at approved sites.
This structure is reflected in regulatory filings (EMA/ national dossiers, including manufacturing site and control strategy disclosures) and in typical MAH supply chains for HIV therapeutics. Public-facing “supplier lists” in secondary data sources are frequently incomplete or geography-specific because:
- Site approval is country- and submission-dependent
- Lot release can shift between sites within the same authorization
- Packaging configurations differ by market
How to map “suppliers” for diligence: what to look for in filings
For business diligence, “supplier” should be mapped to the regulated manufacturing entities named in authorization dossiers and annual product updates:
- Manufacturing site for drug substance (API): the site releasing maraviroc API
- Manufacturing site for drug product: the site compressing/coating/packaging the tablets
- Batch release testing sites: where quality testing is performed for finished product release
- MAH responsibility: ViiV entities and local affiliates that hold authorizations and oversee quality systems
Commercial and regulatory anchors for Selzentry (maraviroc)
- Marketing authorization holder (global origin): ViiV Healthcare (GSK-led HIV franchise, with program ownership for maraviroc commercialization)
- Drug substance: maraviroc (a CCR5 antagonist used in HIV therapy)
These anchors control the set of approved suppliers and the authorized sites within each market.
Key supplier decision points for procurement and risk
When building a supplier map for Selzentry, procurement and technical due diligence should focus on:
- Approved site list: which API and drug product sites are named in regulatory submissions for each territory
- Control strategy stability: whether changes in supplier require prior regulatory notification (site transfer impacts timelines)
- Supply continuity: whether there are multiple approved drug product sites supporting uninterrupted tablet supply
- Packaging configuration: tablet strength and packaging format can drive which CMO is used for a specific lot
Where does the supplier list typically show up (actionable diligence path)
Public supplier identification for Selzentry is most reliable when extracted from:
- Regulatory product dossiers (EMA and national authority documents)
- EMA EPAR assessment reports and related public product documentation for manufacturing disclosures (when available for the specific filing)
- DMF-linked summaries and national drug master file disclosures (where accessible)
- Periodic safety update reports and quality periodic review documentation (often naming manufacturing responsibility and sites)
Key Takeaways
- Selzentry “supplier” is best treated as a regulated network of API and drug product manufacturing sites, not a single vendor.
- ViiV Healthcare is the commercialization and MAH anchor that controls authorized manufacturing footprints.
- A complete supplier map for diligence requires pulling approved API-drug product sites and batch release/testing sites from regulatory dossiers by territory, then validating whether the approved network is multi-site for continuity.
FAQs
-
Is Selzentry supplied by one company worldwide?
No. Selzentry supply uses an approved multi-site model for API and solid oral drug product manufacturing, with site selection varying by market and lot.
-
Who is the marketing authorization holder for Selzentry?
ViiV Healthcare is the global commercialization anchor for maraviroc.
-
What is the difference between an API supplier and a drug product manufacturer for Selzentry?
The API supplier manufactures maraviroc substance; the drug product manufacturer converts API into tablets and runs coating/compression/packaging and finished product release testing.
-
Do supplier sites change over time for Selzentry?
Yes. Approved manufacturing sites can be added or swapped based on capacity, regulatory updates, and quality system readiness.
-
Where can the most reliable supplier information be obtained?
From regulatory product dossiers and public assessment materials that list approved manufacturing and batch release/testing sites for each territory.
References
[1] European Medicines Agency (EMA). EPAR documentation for Selzentry (maraviroc). EMA product page and assessment materials.
